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Abstract
Background: Thyroid physiology is closely related to oxidative changes. The aim of this controlled
study was to evaluate the levels of nutritional anti-oxidants such as vitamin C, zinc (Zn) and
selenium (Se), and to investigate any association of them with parameters of thyroid function and
pathology including benign and malignant thyroid diseases.
Methods: This controlled evaluation of Se included a total of 1401 subjects (1186 adults and 215
children) distributed as follows: control group (n = 687), benign thyroid disease (85 children and
465 adults); malignant thyroid disease (2 children and 79 adults). Clinical evaluation of patients with
benign thyroid disease included sonography, scintigraphy, as well as the determination of fT3, fT4,
TSH, thyroid antibodies levels, Se, Zn, and vitamin C. Besides the routine oncological parameters
(TG, TSH, fT4, ultrasound) Se was also determined in the cases of malignant disease. The local
control groups for the evaluation of Se levels were taken from a general practice (WOMED) as
well as from healthy active athletes. Blood samples were collected between 8:00 and 10:30 a.m. All
patients lived in Innsbruck. Statistical analysis was done using SPSS 14.0. The Ho stated that there
should be no differences in the levels of antioxidants between controls and thyroid disease patients.
Results: Among the thyroid disease patients neither vitamin C, nor Zn nor Se correlated with any
of the following parameters: age, sex, BMI, body weight, thyroid scintigraphy, ultrasound pattern,
thyroid function, or thyroid antibodies. The proportion of patients with benign thyroid diseases
having analyte concentrations below external reference cut off levels were 8.7% of cases for vitamin
C; 7.8% for Zn, and 20.3% for Se. Low Se levels in the control group were found in 12%. Se levels
were significantly decreased in cases of sub-acute and silent thyroiditis (66.4 ± 23.1 μg/l and 59.3 ±
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20.1 μg/l, respectively) as well as in follicular and papillary thyroid carcinoma. The mean Se level in
the control group was 90.5 ± 20.8 μg/l.
Conclusion: The H0 can be accepted for vitamin C and zinc levels whereas it has to be rejected
for Se. Patients with benign or malignant thyroid diseases can present low Se levels as compared
to controls. Low levels of vitamin C were found in all subgroups of patients.
Background
During thyroid hormone synthesis, thyroid tissue is
exposed to H2O2 making it imperative that protective sys-
tems can prevent damage to the gland [1-5]. This tissue
protection can be achieved by selenium-dependent prod-
ucts, e.g. the glutathione peroxidase [6-8]. Serum levels of
selenium (Se) are considered to depict the adequacy
regarding GPx levels and activity [9-11]. In addition to
this, the determination of selenoproteins, e.g. selenopro-
tein P (SePP), can deliver further information on the ade-
quacy of Se levels [12].
Several investigators have previously evaluated Se levels in
patients with benign and malignant thyroid diseases.
These studies demonstrated that hyperthyroidism is asso-
ciated with decreased levels of Se [13-15]. Derumeaux et
al. [16] also concluded that Se might have a protective role
in relation to goiter, and that thyroid hypogenicity
appears to be related to Se levels [16]. In the field of malig-
nant thyroid diseases, decreased tissue levels of zinc (Zn)
and Se, appear to be associated with carcinoma [17]. Stud-
ies based on the Janus serum bank have shown the value
of pre-diagnostic levels of Se in relation to thyroid carci-
noma [18,19].
In experimental settings other micronutrients such as Zn
have also been shown to play a role on thyroid morphol-
ogy and metabolism [20]. It should be kept in mind that
Zn is also an antioxidant [21], while at the same time it
has important functions in relation to immune function
[22,23]. Comparable functions have been described for
Zn and Se together [24,25]. In addition to this, Martin et
al. have described a positive interaction between vitamin
C and Se homeostasis [26].
Besides these thyroid-related data one has to consider the
importance of nutrient antioxidants in a much wider
frame, i.e. in relation to their protective effects on health
[27-30]. An example of this approach is the French
SU.VI.MAX study, where micronutrients have been evalu-
ated in relation to cardiovascular diseases, thyroid disease,
and cancer [31,32]. One central thought behind these
studies has been stated as follows: "Insufficient intake of
antioxidant vitamins and minerals may reduce the body's
capacity to defend itself from the effect of activated oxygen
derivatives on cell processes that play a role in the devel-
opment of cancer and cardiovascular disease [33,34]." It
follows that there is a clinical relevance in the determina-
tion of base line levels of nutrient antioxidants. For this
reason, we designed this investigation in order to evaluate
the levels of nutritional anti-oxidants in a controlled
study, i.e. comparing patients with controls.
Methods
Laboratory determinations of nutritional antioxidants
Blood samples were collected between 8:00 and 10:30
a.m. After centrifugation (1500 g, 15 minutes) serum was
removed and aliquots were frozen and stored at -20°C.
Selenium concentrations in human serum were deter-
mined using a graphite furnace atomic absorption spec-
trometer (Unicam Model Solaar, 939 QZ, Cambridge,
UK) with Zeeman background correction and pyrolytic
carbon-coated graphite tubes. Slit 0.5 and wavelength λ
196.0 nm were used as spectrometer parameters. Speci-
mens were diluted 1:10 with 0.1% HNO3, 0.05% Triton
×100, and 0.05% silicone anti-foaming agent (Merck,
Germany). Palladium nitrate as matrix modifier and
matrix-matched standards for calibration (6.25, 12.5, 25,
and 50 μg/l) were used. Multiple aliquots of a control
pooled serum sample were analyzed during each batch of
analyses (intra-assay CV < 4.5%). Imprecision is shown as
coefficient of variation (CV). In addition, an external con-
trol, (ClinChek-Serum control, Lot No. 323; Recipe
Chemicals and Instruments, Munich, Germany), was ana-
lyzed with each batch. Analyzed values were within the
expected range given by the manufacturer (i.e., Level1:
46–78  μg/L, certified mean concentration: 62.0 μg/L;
Level 2: 84–140 μg/L, certified mean concentration: 112
μg/L), with means of 63.8 ± 6.15 μg/L (n = 19, CV 9.6%)
for Level 1, and 109.9 ± 10.15 μg/L (n = 20, CV 9.2%) for
Level 2 serum analyses.
Serum zinc content was investigated according to Smith et
al. [35] by employing a flame (air-acetylene burner)
atomic absorption spectrometer (Unicam Model Solaar,
939, Cambridge, UK). Bandpass 0.5 nm and wavelength λ
213.9 nm were used as spectrometer parameters. Speci-
mens were diluted 1:10 or 1:5 with double distilled water.
Working standards of zinc containing 0.1, 0.25, 0.5, and
1.0  μg/ml were prepared from stock standard solution
containing 1000 μg Zn/ml. Multiple aliquots of a control
pooled serum sample were analyzed during each batch of
analyses (intra-assay CV < 3.5%). In addition, an external
control, (ClinChek-Serum control, Lot No. 323; RecipeBMC Endocrine Disorders 2008, 8:2 http://www.biomedcentral.com/1472-6823/8/2
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Chemicals and Instruments, Munich, Germany) was ana-
lyzed with each batch. Analyzed values were within the
expected range given by the manufacturer (i.e., Level 1:
636–1060 μg/L, certified mean concentration: 848 μg/L;
Level 2: 1706–2844 μg/L, certified mean concentration:
2275 μg/L), with means of 798 ± 79 μg/L (n = 20, CV
9.9%) for Level 1, and 2037 ± 135 μg/L (n = 20, CV 6.7%)
for Level 2 serum analyses.
For the determination of ascorbic acid a 100 μl volume of
serum was stabilized immediately after preparation by
addition of 100 μl 10% metaphosphoric acid and incu-
bated for 10 minutes at 4°C. Thereafter the sample was
centrifuged at 10000 × g and 4°C. 20 μl of the supernatant
was used for determination of ascorbic acid. The HPLC
method used (flow rate 1.0 ml/min, detection at 245 nm)
is based on the work published by Esteve et al. [36] with
some modifications. The ascorbic acid standard solution
(10 mg/l) was prepared daily in deionized water Milli-
pore-Milli Q. 4-hydroxyacetanilide was used as internal
standard. Multiple aliquots of a control pooled serum
sample were analyzed (intra-assay CV < 3.0%). In addi-
tion, an external quality control (Chromsystems Vitamin
C Plasma control, Lot No. 1906; Chromsystems Instru-
ments and Chemicals GmbH, Munich, Germany), was
analyzed with each batch (inter-assay CV < 5.0%). Deter-
minations of selenium, zinc and ascorbic acid were made
in duplicate, and the analysts were blinded as to the case
status of the specimens.
Vitamin C and zinc in patients with benign thyroid disease
In an initial phase a group of 425 consecutive adult
patients attending the out-patient unit of the Clinical
Department of Nuclear Medicine of the Medical Univer-
sity of Innsbruck were investigated. In these patients the
levels of Zn and vitamin C (n = 415) were determined.
The research protocol was approved by the Institutional
Ethics Committee. Informed consent was obtained from
each subject. Clinical evaluation included sonography,
scintigraphy, and thyroid function parameters. Determi-
nations of fT3, fT4, TSH and thyroid antibodies levels
were done on the Advia Centaur system (Bayer Health
Care, Austria) as described elsewhere [37].
Weight, height and medication were recorded for each
patient. Thyroid ultrasound was done using a Siemens
Sonoline Antares equipped with a VFX13-5 transducer
(Siemens, Erlangen, Germany). RM carried out the ultra-
sound examinations. Thyroid scintigraphy was done on a
Siemens Orbiter gamma camera (Siemens, Erlangen, Ger-
many) after i.v. application of 37 MBq of 99mTc pertech-
netate. Based on the clinical history, the laboratory tests
and the imaging procedures, a final diagnosis was given in
each case. The final diagnoses included: normal thyroid
function (negative thyroid serology), Graves' disease (pos-
itive TSH receptor antibodies), Hashimoto's disease (pos-
itive thyroid serology), sub-acute thyroiditis and silent
thyroiditis [38]. Thyroid function was classified as nor-
mal, hypothyroid or hyperthyroid based on the measured
levels of fT3, fT4 and TSH [37,39,40]
Se levels in patients with thyroid disease
The study included 465 adult patients and 85 pediatric
patients presenting benign thyroid disease, and 164
patients with malignant thyroid disease taking thyroid
medication. Laboratory and ultrasound examinations
were the same as described above. Thyroid scintigraphy
was done neither in the pediatric group nor in the group
with thyroid carcinoma.
Control groups for the evaluation of Se
A control group for the evaluation of Se levels was taken
from a general practice (WOMED, n = 554; 468 females,
mean age 41 ± 11 years; 46 males, mean age 37 ± 15
years). These patients were clinically investigated by RM
and HM. The geographical origin of this control group
was similar to that of the thyroid patients, i.e. all subjects
lived in the province of Tirol in Austria. By this, differ-
ences due to different geographical origin were mini-
mized. In this group of patients the following laboratory
investigations were available: kidney function tests, liver
function tests, red and white cell counts, electrolytes, and
thyroid function tests. The major diagnoses in this group
were: burn-out syndrome, depression, infertility, meno-
pause, GI disorder and DM. None of these entities is
known to be associated with alterations in Se levels. A sec-
ond group of medically controlled subjects included 133
active winter sport athletes not having overt thyroid dis-
ease. This group included 44 females and 89 males with a
mean age of 18.7 ± 4.5 years. Regular medical examina-
tions did not reveal any pathology that can be associated
to changes in Se levels. In the subgroup of 24 ski jumpers,
a total of additional 124 biochemical parameters includ-
ing red and white blood counts, liver function, kidney
function, electrolytes, immunoglobulins, iron metabo-
lism, vitamin B as well as an aminogram were analyzed.
Correlation studies were done in relation to Se levels.
Statistical analysis
Statistical analysis was done using SPSS version 14.
Explorative analyses of correlation were carried out
between diagnostic parameters of thyroid function (fT3,
fT4, TSH, and thyroid antibodies) and the measured levels
of antioxidants. Thyroid characteristics as seen in ultra-
sound and scintigraphy were coded and compared by
cross tabulation with the categorized levels of nutritional
antioxidants. In order to allow for qualitative comparison
with recent data dealing with the nutritional status of
adult Europeans, the cut-off levels for Se, Zn, and vitamin
C were taken from Galan et al. [34]. These levels corre-BMC Endocrine Disorders 2008, 8:2 http://www.biomedcentral.com/1472-6823/8/2
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spond to: 0.75 μM for Se; 10.7 μM for Zn; and 11.4 μM for
vitamin C. Additional external reference levels for Se were
taken from publications that have evaluated the concen-
tration of Se needed to achieve full expression of Se
related products, i.e. deiodinase, glutathione peroxidase
(GPx) and selenoprotein P (SePP) [41-43]. Results were
categorized as being below or above these cut off levels as
well as a percentual fraction of the reference levels.
Finally, differences among the diagnostic groups for each
parameter were analyzed by one way ANOVA using Bon-
ferroni's correction. For all evaluations a p-value < 0.01
was taken as significant. The Ho stated that there are no
differences in the levels of antioxidants between controls
and thyroid disease patients.
Results
General aspects
Neither vitamin C, nor Zn, nor Se levels showed any cor-
relation with sex, age, weight, height, BMI, thyroid func-
tion, ultrasound pattern, nor thyroid morphology. Lack of
association between Se and BMI was also seen even after
classifying the BMI results into subgroups as has been
done recently by Meplan et al. [44]. The descriptive statis-
tics of BMI levels in our study were: mean 23.57 ± 4.5 kg/
m2 (S.D.), the 95th percentile corresponded to a value of
31.7 kg/m2.
In the group of patients with benign thyroid diseases there
were no differences in the levels of Zn or vitamin C
according to the classification of disease type (Table 1).
Due to this lack of correlation, determinations of vitamin
C and Zn were not carried out in the subsequent cases, i.e.
pediatric cases and in the group of patients with thyroid
malignancy.
Comparison of analyte levels with published threshold 
values – the nutritional aspect of the study
In spite of the lack of association of between vitamin C or
Zn levels in relation to thyroid disease it should be
stressed that the overall proportion of thyroid patients
having vitamin C concentrations below the threshold lev-
els reported in the SU.Vi.MAX study [34] was 8.4% of
cases for vitamin C and 7.73% for Zn. The figure for Zn is
similar to the reported one, the figure for vitamin C
exceeds the levels reported.
The percentage of subjects having low levels of Se as com-
pared to the functional threshold level known to be nec-
essary for the maintenance of optimal plasma glutathione
peroxidase [45] is shown in Table 2. In this qualitative
comparison the largest proportions of cases having low Se
levels were seen in children with hyperthyroidism and
polyendocrinopathy, as well as in adults with subacute
and silent thyroiditis, and in follicular carcinoma.
Table 3 shows another qualitative analysis in relation to
the threshold levels known to be necessary for optimal
deiodinase activity, plasma glutathione peroxidase and
selenoprotein P levels [41,42]. While the mean Se value
found in our study was sufficient to cover the require-
ments for deiodinase activity, it was not sufficient neither
for platelet glutathione peroxidase nor for selenoprotein P
expression.
Quantitative analyses of the Se status
Control group
Initial one-way ANOVA showed no difference in the Se
levels in relation to the diagnostic subgroups contained in
the adult control group (burn-out, depression, infertility,
menopause, GI disorders, and DM). It should be men-
tioned that none of these conditions is known to produce
alterations in the concentration of Se. The mean Se level
for the non-thyroid disease control group was 90.5 ± 20.8
μg/l; the 5th percentile corresponded to 65.7 μg/l, and the
95th percentile to 129 μg/l. The control group consisting of
active athletes did not differ from the adult control group.
Selenium status in benign and malignant thyroid disease
One-way analysis of variance of all Se samples, i.e. thyroid
vs. non-thyroid disease patients, revealed significantly
diminished levels (p < 0.001) for all thyroid disease
patients. Among the groups of patients with benign thy-
Table 1: Zn and vitamin C levels in the patients with benign thyroid disease
n mean S.D. SEM 95% confidence interval minimum maximum
low high
Zinc Normal thyroid 276 0,95 0,20 0,01 0,92 0,97 0,41 1,66
Immunogenic thyroid disease 118 0,97 0,19 0,02 0,94 1,01 0,60 1,43
Subacute thyroiditis 31 0,96 0,21 0,04 0,88 1,04 0,42 1,48
All 425 0,96 0,20 0,01 0,94 0,98 0,41 1,66
Vit. C Normal thyroid 273 6,07 2,94 0,18 5,72 6,42 1,80 13,6
Immunogenic thyroid disease 112 6,10 2,63 0,25 5,61 6,59 1,10 13,2
Subacute thyroiditis 29 6,48 3,12 0,58 5,29 7,66 0,70 12,8
All 414 6,11 2,87 0,14 5,83 6,39 0,70 13,6BMC Endocrine Disorders 2008, 8:2 http://www.biomedcentral.com/1472-6823/8/2
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roid disease, the Se levels of those with subacute and with
silent thyroiditis were significantly lower as compared to
the other diagnostic groups. In sub-acute and silent thy-
roiditis the measured levels were: 66.4 ± 23.1 μg/l and
59.3 ± 20.1 μg/l, respectively. In the groups of patients
with thyroid malignancy, those presenting follicular and
papillary types of carcinoma showed also diminished Se
concentrations (76.9 ± 21.1 μg/l and 80.4 ± 19.8 μg/l,
respectively). Children with thyroid disease and polyen-
docrinopathy had low Se levels similar to those found in
adults with thyroiditis (mean 66.9 μg/l). The minimal lev-
els of Se were observed in the group of adult patients with
benign thyroid disease (range 20.7 to 30 μg/l) (Table 4).
Correlation analyses for Se and TSH, Se and BMI and of Se
and thyreoglobulin failed to demonstrate any significant
association. In a similar fashion, the ample biochemical
analysis of the ski jumper control group with 124 param-
eters revealed no associations for Se in relation to white
and red blood counts, electrolytes, liver and kidney func-
tion tests, cortisol, testosterone, iron, folic acid, vitamin
B12, immunoglobulins, and aminogram data including
methionine levels.
Discussion
General evaluation in relation to external reference levels
Our study was designed as a controlled one in order to
evaluate the levels of nutritional antioxidants, i.e. Se, Zn
and vitamin C, in relation to morphological and func-
tional parameters of benign and malignant thyroid dis-
ease. These nutritional parameters were chosen due to
their physiological role in inflammation [46] as well as in
Table 3: Se levels expressed in percentage of threshold levels in relation to deiodinases (IDI), plasma glutathione peroxidase (GPx), 
and selenoprotein P (SePP) [41,42]
measured mean Se Se related parameters and their threshold levels in μM
IDI GPx SePP
μM 0,82 1,2 1,7
Controls 1,14 139,51 * 95,33 67,29
Ski jumpers 1,05 128,21 87,61 61,84
Ski runners 1,09 133,50 91,22 64,39
Children Hypothyroidism 1,04 126,38 86,36 60,96
Children Hashimoto 0,98 119,33 81,54 57,56
Children hyperthyroidism 0,83 101,67 69,48 49,04
Children Poly 0,85 103,19 70,51 49,77
Thyroid normal 1,02 124,97 85,40 60,28
Thyroid immunogenic 1,04 126,39 86,37 60,96
Subacute thyroiditis 0,84 102,29 69,90 49,34
Silent thyroiditis 0,75 91,40 62,45 44,09
anaplastic Ca 1,20 146,46 100,08 70,64
follicular Ca 0,97 118,54 81,00 57,18
foll.-papillary Ca 0,87 106,14 72,53 51,20
giant cell papillary Ca 1,06 129,02 88,16 62,23
invasive Ca 0,95 115,31 78,79 55,62
microcarcinoma 0,86 104,98 71,74 50,64
papillary Ca 1,02 123,95 84,70 59,79
unclassified Ca 0,96 117,02 79,96 56,45
All (n = 1401) 1,06 129,81 88,71 62,62
*: the figures are given as percent of the threshold level (% = measured Se concentration * 100/threshold level)
Table 2: Percentage of subjects with Se levels below the 
threshold for optimal plasma glutathione peroxidase [45]
% of patients with
Study groups low Se sufficient Se
Controls 33,0 67,0
Ski jumpers 50,0 50,0
Ski runners 43,1 56,9
Children hypothyroidism 48,9 51,1
Children Hashimoto 46,4 53,6
Children hyperthroidism 75,0 25,0
Children polyendocrinopathy 66,7 33,3
Thyroid normal 49,5 50,5
Thyroid immunogenic 46,6 53,4
Subacute thyroiditis 76,0 24,0
Silent thyroiditis 84,6 15,4
follicular Ca 64,3 35,7
foll papillary Ca 63,6 36,4
giant cell papillary Ca 40,0 60,0
invasive Ca 75,0 25,0
papillary Ca 52,1 47,9BMC Endocrine Disorders 2008, 8:2 http://www.biomedcentral.com/1472-6823/8/2
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anti-oxidative processes [47]. Oxidative processes in gen-
eral are matter of current research in both benign and
malignant disease since they are linked to aging, to gen-
eral disease conditions as well as to increased mortality
rates in the general population [27,30,48-51]. Through
the use of local control groups we expected to be able to
differentiate the normal and the pathological conditions
[52]. Based on one way ANOVA analysis Ho could be
rejected for Se levels, i.e. Se levels are indeed different
between patients and controls.
From a nutritional, qualitative point of view, our study
documents diminished levels of vitamin C and Se in our
patients as compared to recent data from the SU.VI.MAX
study [34]. On the other hand, plasma Zn levels were
found to be unrelated to thyroid function or morphology.
Due to the predominantly intracellular distribution of Zn
[53-59] a different analytical approach, i.e. determination
of erythrocyte Zn levels, might have been more adequate
to differentiate patients with hyperthyroidism from those
with thyroiditis [60-64] as well as those with thyroid asso-
ciated orbitopathy [46].
The role of vitamin C in thyroid disease
Clinical studies on the importance of vitamin C in rela-
tion to thyroid disease are scarce. In 1977 Dubey et al.
described low levels of ascorbic acid in patients with
hyperthyroidism [65]. Similar results have been presented
by Ademoglu et al. [66] and Alicigüzel et al. [67]. Mohar
Kumar et al. described also low levels of vitamin C in
hyperthyroidism, while at the same time lipid peroxides,
glucose, and HbA1C levels were elevated [68]. It follows
that both data from the literature as well as from our study
show that vitamin C levels can be low in patients with
benign thyroid disease. Low levels of vitamin C can pre-
dispose to endothelial changes [69,70], a situation which
can also be negatively influenced by diminished thyroid
function [71,72]. Our failure to demonstrate an associa-
tion between vitamin C levels and benign thyroid disease
could be explained through the relatively short half life of
vitamin C of 10–20 days [73]. Nonetheless, interactions
between vitamin C and Se have been described [26,74-77]
by which low levels of vitamin C could affect Se metabo-
lism and action.
Se in relation to amino acids and other biochemical 
parameters and BMI
Early studies on the bioavailability of selenomethionine
mentioned potential interactions between methionine
and Se uptake [78]. Based on an extensive biochemical
analysis with 124 parameters including an aminogram,
we were not able to find any relation between Se and the
parameters studied including methionine. The associa-
tion between Se and methionine appears to be possible
within the frame of malnutrition together with methio-
nine deficiency as has been shown in experimental set-
tings [79]. In our study, none of the patients presented
malnutrition.
Table 4: One-way ANOVA (Bonferroni) analysis of the Se levels
n mean S.D. SEM 95% confidence interval minimum maximum p-value vs 
controls
low high
Controls 554 90,49 20,85 0,89 88,75 92,23 47,34 187,20
Ski jumpers 24 83,17 26,51 5,41 71,97 94,36 51,30 136,00 1
Ski runners 109 86,59 21,04 2,02 82,60 90,59 45,82 165,00 1
Children hypothyroidism 47 81,98 22,53 3,29 75,36 88,59 41,30 131,00 1
Children Hashimoto 28 77,40 23,54 4,45 68,27 86,53 40,50 119,30 0,308
Children hyperthyroidism 4 65,95 13,99 6,99 43,69 88,21 53,40 81,00 1
Children polyendocrinopathy 6 66,93 20,92 8,54 44,98 88,89 43,70 96,20 1
Thyroid normal adults 283 81,06 21,62 1,29 78,53 83,59 30,10 172,80 < 0,001
Thyroid immunogenic adults 131 81,98 24,82 2,17 77,69 86,27 28,50 163,00 0,009
Subacute thyroiditis adults 25 66,35 23,13 4,63 56,81 75,90 31,30 119,40 < 0,001
Silent thyroiditis adults 26 59,28 20,13 3,95 51,15 67,42 20,70 96,90 < 0,001
anaplastic Ca 3 95,00 13,25 7,65 62,08 127,92 87,35 110,30 1
follicular Ca 42 76,89 21,16 3,26 70,30 83,49 47,38 124,00 0,015
foll papillary Ca 11 68,85 18,57 5,60 56,37 81,33 46,84 96,77 0,176
giant cell papillary Ca 10 83,69 26,88 8,50 64,46 102,91 51,10 113,40 1
invasive Ca 8 74,80 18,28 6,46 59,51 90,08 60,68 103,10 1
microcarcinoma 4 68,10 9,54 4,77 52,91 83,28 59,83 76,36 1
papillary Ca 73 80,40 19,87 2,33 75,77 85,04 50,72 121,80 0,031
unclassified Ca 13 75,91 20,72 5,75 63,38 88,43 47,38 110,30 1
All 1401 84,20 22,50 0,60 83,02 85,38 20,70 187,20BMC Endocrine Disorders 2008, 8:2 http://www.biomedcentral.com/1472-6823/8/2
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In the recent analysis of genetic SePP polymorphisms,
Méplan et al. identified an association of BMI with Se lev-
els for subjects having a BMI > 25 kg/m2 [44]. In our study
we were not able to find a similar association.
Se in benign and malignant thyroid disease
Previous investigators have looked at Se levels in whole
blood in relation to hyperthyroidism [13]. Beckett et al.
reported lower values of Se for untreated Graves' disease
(mean 88.9 μg/l) as compared to treated patients (mean
107.2 μg/l). The authors suggested that hyperthyroidism
is responsible for low Se levels. Aihara et al. have also
shown low erythrocyte levels of Se in cases of hyperthy-
roidism [80]. Using plasma determinations, Reglinski et
al. have also shown low Se levels in hyperthyroidism [14].
These authors were able to document an increase in Se
concentration after anti-thyroid treatment, however the
mean Se value was still lower than that of the controls
[14]. The question of Se normalization after remission of
hyperthyroidism has been looked at recently by Werten-
bruch et al. [81]. The authors could not find a normaliza-
tion of Se in the remission phase: Se levels in Graves'
disease without and with remission were 71.7 μg/l and 73
μg/l, respectively. In our study we have not found any rela-
tion between thyroid function parameters and Se levels in
benign thyroid disease, so that we cannot lend support to
Beckett's theory. Furthermore, we did not find any rela-
tion between Se and thyroid function parameters in the
group of oncological patients who were taking T4 medica-
tion in a suppressive dose.
An analysis based on whole blood determinations of Se
done by Kucharzewski et al. reported lower Se levels for
thyroid carcinoma, nodular goiter, Graves' disease and
thyroiditis as compared to normals [15]. While their study
revealed lower Se levels in the 21 patients with thyroid
carcinoma, there was no information as to the histological
type of carcinoma. Out of 164 patients with thyroid carci-
noma investigated by us only those with follicular or pap-
illary types had low Se levels. Due to study design, we
cannot fully confirm the observations obtained from the
JANUS serum bank relating pre-diagnostic low Se levels
with thyroid carcinoma [18]. Our data has discarded any
association between Se and Tg.
Selenium levels in pediatric patients
Dealing with Se levels in children differs from adult sub-
jects since an age related increase can be seen. Se levels in
children in the pre-school and school age are similar to
those found in adults while younger patients have lower
levels [82,83]. In 1992 Tiran et al. failed to observe this
increase of Se levels for Austrian children [84,85]. The Se
levels reported by Tiran et al. are far below the levels
required for adequate expression of selenoproteins. Even
though the mean level of Se in our pediatric patients is
higher than that seen in 1992, a tendency to lower Se val-
ues can be seen in children with hyperthyroidism and
with polyendocrinopathy. These situations have not been
described before in the literature. Low levels of Se have
been reported in Polish pediatric patients presenting thy-
roid diseases due to iodine deficiency [86]. Even after cor-
rection of iodine deficiency, children still had low Se
levels [87]. Due to iodine supplementation programs in
Austria, iodine deficiency is now rare [88], however Se lev-
els can still be suboptimal, as we have documented here.
On experimental grounds, Ruz et al. have nicely demon-
strated the effects of single and combined deficiency situ-
ations involving iodine, Se, and Zn [20].
Situations leading to low Se levels
Since our results point out the fact that a significant pro-
portion of patients with thyroid disease have low levels of
Se, it is important to analyze some of the known causes
related to low Se levels [45,89,90] which might play a role
in our patients. The central regulator of Se levels is the ade-
quacy of supply, so that malnutrition in different degrees
will lead to low Se levels [90-92]. Minor surgical interven-
tions [93] and intensive care situations [94,95] can also
induce a drop of Se concentrations. Nutritional studies
have shown that feeding a low Se diet for 30 days can
induce a drop of the plasma Se levels [96]. None of these
conditions, however, were found in our subjects.
Stressful life events have been implicated in the etiology
of thyroid disorders [97-103] and psychological stress per
se can lead to diminished levels of Se [104]. In addition to
this both physical and psychological stress can also induce
changes in trace elements [105], e.g. to low levels of Mg
[106], and low Mg levels can affect Se absorption
[107,108]. In a previous study we have documented an
altered relationship between Mg and Ca in patients with
thyroid associated orbitopathy [46], thus lending support
to this postulate.
In a general sense, viral infections can be considered to
pose a stress to the organism [109-114]. Se deficit can
increase the virulence of some infections such as with cox-
sackie virus in relation to heart disease [115]. Several
authors have even proposed a viral etiology of thyroiditis,
however this has not been confirmed neither in De Quer-
vain's thyroiditis nor in Graves' disease [116-119]. Should
a Se deficiency be present a-priori, viral infections can turn
aggressive at least in animal models [120]. Similar associ-
ations have been described in HIV infections [121], how-
ever Beltran et al. could not find evidence for an
autoimmune mechanism of thyroid disease in HIV
patients [122].
Low Se levels can be seen in association with the acute
phase of several pathological conditions [123]. Maehira etBMC Endocrine Disorders 2008, 8:2 http://www.biomedcentral.com/1472-6823/8/2
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al. extended these observations by in-vitro experiments
where it could be shown that low Se influences the activa-
tion of NF-Kappa-B, whereas a state of normal Se inhibits
the NF-Kappa-B mechanisms that can lead to increased
CRP levels [124]. An inflammatory reaction appears to
depend on the interaction between IL-6, TNF and seleno-
protein S [125]. Selenium and parameters of infection or
inflammation have been recently described as a situation
of negative correlation between Se and CRP and IL-6 [95].
Results from the MONICA/KORA Augsburg study have
shown that normal Se levels are related to vitamins C and
E as well as to low CRP values [126].
In a study presented by Pearce et al. [127] a central role of
elevated CRP levels in thyroid disease could not be found.
Severe health impairment such as found in sepsis and
multiorgan failure, on the other hand, can indeed alter Se
levels [95]. Clinical practice with thyroid disease patients
however, does not lend evidence to the presence of a
severe infection at the time an out-patient consultation
takes place. A different situation could be expected in
cases of chronic infection or parenteral nutrition [128].
Biochemical changes in Se deficiency
Besides the diminished levels of Se in cases of deficiency a
series of Se-dependent proteins can be found to be altered
in such situations. This has been shown elegantly in Fin-
land after Se supplementation was introduced in the
1980s: supplementation with Se led to an increase of the
levels of Se and of SePP. Once Se repletion was achieved,
SePP levels did not change significantly when Se was given
[42]. In cases of Se deficiency, the changes in SePP are tis-
sue specific [129]. In addition to this feature a recent study
has documented the influence of gender and genetic pol-
ymorphisms on the response pattern of SePP to Se supple-
mentation [44]. Analyses of Se together with
selenoproteins, which can be considered to be a better
indicator of Se status [130,131], have not been carried out
in cases of thyroid disease.
What to do in face of low Se levels in patient with thyroid 
disease?
The description of deficient nutritional situations belongs
to the classical approach used in nutrition research in
order to identify causes and to treat them by substitution
[132]. In the previous section we have tried to delineate
some of the changes that can be expected to happen
within the setting of low Se levels in relation to inflamma-
tion and which might change during supplementation.
The use of nutrient supplementation which is not based
on the determination of nutrient levels cannot be
expected to achieve beneficial effects since the needed
dose and the target parameters might be incorrect. In
addition, the chemical form of the nutrient has to be cho-
sen adequately [133]. Reading the description of the indi-
vidual studies cited in the meta analysis done by
Bjelakovic et al. [134] it is easy to recognize why the ana-
lysts did not find positive effects of supplementation pro-
cedures: some studies did not measure the basal levels
prior to intervention, and the doses and chemical forms of
the preparations differed greatly.
At the time we carried out this study, several Se supple-
mentation trials for patients with autoimmune thyroid
disease were published [135-138]. In these studies the
common denominator was the drop in the level of thy-
roid antibodies, i.e. a better nutritional status induced
changes in the humoral arm of the immune system. The
study by Gärtner et al. utilized 200 μg of a liquid formula-
tion of sodium selenite over a period of 3 months. In the
verum group Se levels increased from 0.87 to 1.09 μM; at
the same time thyroid peroxidase antibody levels dropped
by 37% [135]. Duntas et al. [136] carried out "arbitrary"
evaluations in a subgroup of the patients studied. They
found a basal Se level of 75 μg/l. Intervention was done
using selenomethionine at a dose of 200 μg/d and were
able to observe a greater drop of thyroid antibody levels of
46% after 3 months, and of 55.5% after 6 months of ther-
apy. Turker and colleagues compared the efficacy of 100
μg and 200 μg of selenomethionine concluding that better
effects could be reached by the higher dose [137]. Mazo-
pakis et al. [138] used a dose of 200 μg selenomethionine
and observed also a drop in the levels of thyroid peroxi-
dase antibodies. None of the studies found changes in the
levels of thyroid hormones. Finally Negro et al. [139]
studied a group of pregnant women who presented thy-
roid peroxidase antibodies. The base-line Se levels ranged
between 78.2 and 80.9 μg/l. Under treatment with 200 μg
selenomethionine, Se levels remained significantly ele-
vated, app. 105 μg/l, while the untreated group showed a
transient drop of Se at 30 weeks of pregnancy. Se supple-
mentation was associated with a lower incidence of
hypothyroidism and thyroid inflammation. In our previ-
ous preliminary series Se substitution with 200 μg of
selenomethionine was instituted when Se levels were
lower than 70 μg/l. Besides a drop of thyroid antibodies,
we were also able to document an increase of thyroid
function, i.e. latent hypothyroidism was corrected [140].
Conclusion
From a global point of view, we can state that nutritional
deficiencies in relation to Se and vitamin C have been
found in our study of Austrian patients. These findings
contradict the official Austrian opinion contained in the
Austrian Nutrition Report 2003 [141].
Within the wide spectrum of patients with thyroid disease
studied herein, the most salient feature is that of dimin-
ished levels of Se in cases of sub-acute and silent thyroidi-
tis, as well as in the setting of pediatric patients withBMC Endocrine Disorders 2008, 8:2 http://www.biomedcentral.com/1472-6823/8/2
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hyperthyroidism and polyendocrinopathy, and in cases of
differentiated thyroid carcinoma. The mechanisms that
lead to low Se levels are not yet known. Loss of differenti-
ation of thyroid carcinoma has been recently postulated
to be related to Se metabolism and indirectly to octreotide
uptake [142].
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